Hormone replacement therapy for primary and secondary prevention of heart disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Cardiovascular disease is the leading cause of death in women. In pooled analysis, observational studies have shown a 50% reduction in death and myocardial infarction among users of hormone replacement therapy (HRT) for the primary and secondary prevention of cardiovascular disease. The first randomized trial of HRT for secondary prevention of heart disease found no benefit to therapy (Heart and Estrogen/progestin Replacement Study [HERS]). Even after 6–8 years of follow-up, there was still no cardiovascular benefit from the use of HRT (HERS II). HRT was associated with a 50% increased risk of heart attacks within the first year as well as an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) (relative risk [RR] 2.89) and gallbladder disease (RR 1.38). The Estrogen Replacement and Atherosclerosis trial found no evidence that HRT slowed the progression of subclinical angiographic disease either. This was despite a favorable effect on high-density lipoprotein and low-density lipoprotein. The first randomized trial of HRT for the primary prevention of heart disease found no overall benefit (Women’s Health Initiative). The combination of estrogen and progestin resulted in a 29% increase in heart attacks, 41% increase in stroke, a doubling of thrombotic events (DVT and PE), as well as a 26% increase in breast cancer. The risk for thrombotic events was greatest in the first year whereas the risk of breast cancer increased progressively with duration of therapy. HRT is no longer recommended for the primary or secondary prevention of cardiovascular disease or stroke. It may still be considered for short-term relief of menopausal symptoms in women without high-risk conditions, but alternatives exist.
- Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47–63. CrossRef
- Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. CrossRef
- Grady D, Herrington D, Bittner V, et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002, 288:49–57. Longer-term follow-up of the HERS trial. CrossRef
- Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000, 343:522–529. Randomized trial looking at the effects of estrogen on atherosclerosis. CrossRef
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial [no authors listed]. JAMA 2002, 288:321–333. Randomized trial of HRT in healthy women.
- Kawas C, Resnick S, Morrison A, et al.: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 1997, 48:1517–1521.
- Manson JE, Martin KA: Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001, 345:34–40. CrossRef
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial [no authors listed]. JAMA 1995, 273:199–208.
- West SG, Hinderliter AL, Wells EC, et al.: Transdermal estrogen reduces vascular resistance and serum cholesterol in postmenopausal women. Am J Obstet Gynecol 2001, 184:926–933. CrossRef
- Bostom AG, Gagnon DR, Cupples LA, et al.: A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994, 90:1688–1695.
- Kim CJ, Min YK, Ryu WS, et al.: Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women: influence of various progestogens and duration of therapy. Arch Intern Med 1996, 156:1693–1700. CrossRef
- Cushman M, Legault C, Barrett-Connor E, et al.: Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 1999, 100:717–722.
- Wakatsuki A, Okatani Y, Ikenoue N, et al.: Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002, 105:1436–1439. CrossRef
- Ridker PM, Buring JE, Shih J, et al.: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731–733.
- Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811. CrossRef
- Ganz P: Vasomotor and vascular effects of hormone replacement therapy. Am J Cardiol 2002, 90:F11-F16. CrossRef
- Williams JK, Adams MR, Herrington DM, et al.: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992, 20:452–457. CrossRef
- Lieberman EH, Gerhard MD, Uehata A, et al.: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936–941.
- Hodis HN, Mack WJ, Lobo RA, et al.: Estrogen in the prevention of atherosclerosis: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2001, 135:939–953.
- Bush TL, Barrett-Connor E, Cowan LD, et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75:1102–1109.
- Rosenberg L, Armstrong B, Jick H: Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med 1976, 294:1256–1259. CrossRef
- Grodstein F, Manson JE, Colditz GA, et al.: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000, 133:933–941. Nurses’ Health Study looking at HRT in otherwise healthy women.
- Grodstein F, Stampfer MJ, Falkeborn M, et al.: Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999, 5:476–480. CrossRef
- Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 151:75–78. CrossRef
- Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1984, 313:1038–1043. CrossRef
- Sullivan JM, Vander Zwaag R, Hughes JP, et al.: Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990, 150:2557–2562. CrossRef
- Psaty BM, Heckbert SR, Atkins D, et al.: The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994, 154:1333–1339. CrossRef
- O’Keefe JH Jr, Kim SC, Hall RR, et al.: Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1–5. CrossRef
- Newton KM, LaCroix AZ, McKnight B, et al.: Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997, 145:269–277.
- Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. Ann Intern Med 2001, 135:1–8.
- Heckbert SR, Kaplan RC, Weiss NS, et al.: Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709–1713. CrossRef
- Alexander KP, Newby LK, Hellkamp AS, et al.: Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001, 38:1–7. CrossRef
- Barrett-Connor E, Grady D: Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998, 19:55–72. CrossRef
- Pedersen AT, Lidegaard O, Kreiner S, et al.: Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997, 350:1277–1283. CrossRef
- Simon JA, Hsia J, Cauley JA, et al.: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001, 103:638–642.
- Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243–1249. CrossRef
- Upmalis DH, Lobo R, Bradley L, et al.: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000, 7:236–242. CrossRef
- Wassmann S, Laufs U, Stamenkovic D, et al.: Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002, 105:2083–2091. CrossRef
- Delmas PD, Bjarnason NH, Mitlak BH, et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641–1647. CrossRef
- Costantino JP, Keller LH, Ives DG, et al.: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997, 89:776–782. CrossRef
- Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993, 85:1398–1406. CrossRef
- Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371–1388. CrossRef
- Hormone replacement therapy for primary and secondary prevention of heart disease
Current Treatment Options in Cardiovascular Medicine
Volume 5, Issue 1 , pp 25-33
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links